These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

764 related articles for article (PubMed ID: 26149185)

  • 1. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
    Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
    Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients.
    Snir O; Widhe M; Hermansson M; von Spee C; Lindberg J; Hensen S; Lundberg K; Engström A; Venables PJ; Toes RE; Holmdahl R; Klareskog L; Malmström V
    Arthritis Rheum; 2010 Jan; 62(1):44-52. PubMed ID: 20039432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.
    Zhu T; Feng L
    Int J Rheum Dis; 2013 Apr; 16(2):157-61. PubMed ID: 23773638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of anti-modified citrullinated vimentin with subclinical atherosclerosis in early rheumatoid arthritis compared with anti-cyclic citrullinated peptide.
    El-Barbary AM; Kassem EM; El-Sergany MA; Essa SA; Eltomey MA
    J Rheumatol; 2011 May; 38(5):828-34. PubMed ID: 21362765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of anti-modified citrullinated vimentin in rheumatoid arthritis.
    Maraina CH; Nurdayana AK; Rusni D; Azwany Y
    Int J Rheum Dis; 2010 Oct; 13(4):335-9. PubMed ID: 21199468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The anti-mutated citrullinated vimentin response classifies patients with rheumatoid arthritis into broad and narrow responders.
    Engelmann R; Brandt J; Eggert M; Karberg K; Krause A; Neeck G; Mueller-Hilke B
    J Rheumatol; 2009 Dec; 36(12):2670-4. PubMed ID: 19884278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study.
    Syversen SW; Goll GL; van der Heijde D; Landewé R; Lie BA; Odegård S; Uhlig T; Gaarder PI; Kvien TK
    Ann Rheum Dis; 2010 Feb; 69(2):345-51. PubMed ID: 19648126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis.
    Gonzalez-Lopez L; Rocha-Muñoz AD; Ponce-Guarneros M; Flores-Chavez A; Salazar-Paramo M; Nava A; Cardona-Muñoz EG; Fajardo-Robledo NS; Zavaleta-Muñiz SA; Garcia-Cobian T; Gamez-Nava JI
    J Immunol Res; 2014; 2014():536050. PubMed ID: 24804270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison between IgG- and IgA-class antibodies to cyclic citrullinated peptides and to modified citrullinated vimentin in early rheumatoid arthritis and very early arthritis.
    Svärd A; Kastbom A; Söderlin MK; Reckner-Olsson Å; Skogh T
    J Rheumatol; 2011 Jul; 38(7):1265-72. PubMed ID: 21459947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptidyl arginine deiminase type IV (PADI4) haplotypes interact with shared epitope regardless of anti-cyclic citrullinated peptide antibody or erosive joint status in rheumatoid arthritis: a case control study.
    Bang SY; Han TU; Choi CB; Sung YK; Bae SC; Kang C
    Arthritis Res Ther; 2010; 12(3):R115. PubMed ID: 20537173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis.
    Dejaco C; Klotz W; Larcher H; Duftner C; Schirmer M; Herold M
    Arthritis Res Ther; 2006; 8(4):R119. PubMed ID: 16859519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis.
    Kuna AT; Lamot L; Miler M; Harjacek M; Simundic AM; Vrkic N
    Clin Chem Lab Med; 2009; 47(12):1525-30. PubMed ID: 19842993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.
    Hitchon CA; Alex P; Erdile LB; Frank MB; Dozmorov I; Tang Y; Wong K; Centola M; El-Gabalawy HS
    J Rheumatol; 2004 Dec; 31(12):2336-46. PubMed ID: 15570632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The significance of serum peptidylarginine deiminase 4 in rheumatoid arthritis].
    Qian L; Shi HX; Li XP; Zhang H; Li XM; Wang GS
    Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):107-10. PubMed ID: 21418828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of anti-CCP antibodies, proximal interphalangeal joint involvement, HLA-DRB1 shared epitope, and PADI4 as risk factors for the development of rheumatoid arthritis in palindromic rheumatism.
    Tamai M; Kawakami A; Iwamoto N; Arima K; Aoyagi K; Eguchi K
    Scand J Rheumatol; 2010 Aug; 39(4):287-91. PubMed ID: 20476860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.
    Ferucci ED; Darrah E; Smolik I; Choromanski TL; Robinson DB; Newkirk MM; Fritzler MJ; Rosen A; El-Gabalawy HS
    J Rheumatol; 2013 Sep; 40(9):1523-8. PubMed ID: 23908443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: association with cigarette smoking and HLA-DRB1 'shared epitope' alleles.
    Wagner CA; Sokolove J; Lahey LJ; Bengtsson C; Saevarsdottir S; Alfredsson L; Delanoy M; Lindstrom TM; Walker RP; Bromberg R; Chandra PE; Binder SR; Klareskog L; Robinson WH
    Ann Rheum Dis; 2015 Mar; 74(3):579-86. PubMed ID: 24297382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of citrullinated collagen type II and its antibodies in rheumatoid arthritis].
    Tian X; Bi LQ; Li ZG
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(33):2334-8. PubMed ID: 17156630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control study.
    Hoppe B; Häupl T; Gruber R; Kiesewetter H; Burmester GR; Salama A; Dörner T
    Arthritis Res Ther; 2006; 8(2):R34. PubMed ID: 16469113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.